Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/2018: Research Grant Cycle
Learn more

04/01/2019: 2019 Fellow Exam Application Deadline
Learn more

06/01/2019: Research Grant Cycle

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

EDUCATION

Different Advanced Course

What is it in today’s otolaryngology practice that is resonating as a hot topic? Where are the novel treatment strategies? What is today’s typical otolaryngology practice or more specifically the typical AAOA member’s practice?  These are the questions we try to address when building out our Advanced Course in Allergy & Immunology. Read More

Codes/Guidelines

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

IFAR

Editor in Chief Search
The ARS-AAOA IFAR LLC is pleased to announce its search for Editor in Chief, term beginning April 2020. Read More

IFAR Impact Factor: 2.135

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2018 Advanced Course in Allergy & Immunology
December 6-8 | Atlanta, GA
Learn More and Register

2019 Interactive Allergy & Rhinology Course
February 8-10, 2019 | Dallas, TX
Save the Date

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Save the Date

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

OTC Allergy Medications

There seem to be more and more medications available for allergy treatment that  you can now purchase over the counter.
The FDA is allowing previously prescription only drugs to be made available directly to the consumer without a prescription — adding more to the over-the-counter options in the healthcare aisles.

Read More

News and Updates

Welcome to the 2017 AAOA Annual Meeting

Offering Winning Strategies for Your Practice By Cecelia Damask, DO, Director of Educational Programs, and Matthew…

read more

Socio-Economic Committee Update May 2017

By AAOA Leadership Change is the only constant in life and medicine to borrow from…

read more
Menu

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr.

FDA Commissioner Scott Gottlieb, M.D states that “This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages…”

Read More